
AZD1222 claims 79% effecacy in pivotal US study
For exactly one day, the belief that AstraZeneca's COVID-19 vaccine AZD1222 may be better than its reputation lasted. But because the ailing vaccine...

Roche in take-over deal with GenMark Diagnostics
The US$1.8bn cash merger – US$ 24.05 per share – is set to close in Q2/2021. The price represents a premium of approximately 43% to GenMark’s...

B.1.1.7 variant associated with higher mortality
Previous reports from British autorities that suggested a 30 to 100% higher mortality of B.1.1.7 than of the previously dominant form in Europe are...

Biomarker identifies high-risk COVID-19 patients
The findings of virologists headed by Elisabeth Puchhammer-Stöckl from the Medical University Vienna may pave the way to early identification of...

EU approves second COVID-19 vaccine
The EU has secured a total of 160 million doses of mRNA-1273 from the US-American manufacturer Moderna, which has outsourced production sites on the...

EU life science PPPs face less budget in Horizon Europe
The EU’s Public-Private Partnerships (PPPs), which have been under fire by the European Parliament and were renamed into ‘European Partnerships‘, are...

Cellink AB acquires Ginolis Oy for €70m
Under the agreement, Cellink AB is set to acquire all shares for a purchase price on cash- and debt-free basis of €70m. Forty per cent of the...